🔴 Doximity is trading 5% down in pre-market with no clear company-specific catalyst

Doximity is trading at $25.03, down 5.01% in pre-market on September 28, with no newly reported company-specific catalyst identified.

• The latest company news located was its September 22 announcement about being named a leading clinical AI benchmark, which does not clearly explain the decline.
• Broader risk sentiment is weaker after President Trump rejected Iran’s Strait of Hormuz proposal; oil rose and U.S. stock futures slipped, adding pressure to markets.
• Supplied index moves are negative but below 0.5%, so they do not independently establish a broad-market explanation for Doximity’s larger move.